
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group Inc is projected to experience EBITDA margin expansion from approximately 16% today to the mid-20s over the next few years, supported by sustained high single-digit sales growth. The company boasts a robust balance sheet and durable margins, positioning it favorably for continued growth within the expanding market for advanced diabetes technology. Additionally, the International segment's consistent double-digit sales growth, coupled with new product launches like MiniMed Go and the Instinct CGM sensor, is expected to further drive revenue growth in the future.
Bears say
Minimed Group Inc. is facing a negative financial outlook primarily due to anticipated declines in key metrics, including negative earnings per share (EPS) as new products are launched, with recovery projected only in the long term. Regulatory risks are significantly impacting the company's ability to bring devices and algorithms to market, evidenced by a past FDA warning letter that has contributed to delays in product approvals and a competitive disadvantage in the diabetes management market. Furthermore, penetration rates for Minimed’s products remain notably low among Type 1 and Type 2 insulin-dependent patients in both developed and emerging markets, combined with a historical struggle to meet product development timelines that may hinder the company's competitive position.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares